Form 4: Immunic Inc. Chief Medical Officer Andreas Muehler Reports Stock Option Grant

Immunic Inc.'s Chief Medical Officer, Andreas Muehler, was granted stock options for 315,000 shares on December 4, 2024.

Summary

• Andreas Muehler, Chief Medical Officer of Immunic Inc., received stock options for 315,000 shares.
• The options were granted on December 4, 2024, with an exercise price of $1.25 per share.
• The options vest over a period of 48 months, with 25% vesting on the first anniversary of the grant date and the remainder vesting monthly over the following 36 months.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of a stock option grant, which is generally positive for aligning management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of 48 months with a cliff at 12 months is a common structure for these types of grants.
• The exercise price of $1.25 is specific to the company's current stock price and valuation.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning management's interests with the company's long-term performance.
• The grant incentivizes the Chief Medical Officer to contribute to the company's success.

Key Dates

Keywords

stock options, executive compensation, insider trading, Immunic Inc., IMUX, Andreas Muehler, Chief Medical Officer